Oct 25 (Reuters) - Bavarian Nordic said on Wednesday the U.S. Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has voted in favor of recommending the routine use of Jynneos vaccine for adults at risk of mpox. (Reporting by Mrinmay Dey in Bengaluru; Editing by Anil D'Silva)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
152.2 DKK | +2.22% | +1.70% | -13.98% |
Mar. 13 | Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults | MT |
Mar. 13 | Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.98% | 1.66B | |
+26.51% | 661B | |
+26.94% | 566B | |
-6.54% | 352B | |
+20.40% | 332B | |
+2.58% | 283B | |
+13.72% | 231B | |
+5.15% | 200B | |
-9.12% | 195B | |
-5.05% | 145B |
- Stock Market
- Equities
- BAVA Stock
- News Bavarian Nordic A/S
- US CDC panel recommends Bavarian Nordic's vaccine for adults at risk of mpox